Library / Laws / 116th Congress / House Bills / H.R. 2375
H.R. 2375
To prohibit prescription drug companies from compensating other prescription drug companies to delay the entry of a generic drug, biosimilar biological product, or interchangeable biological product into the market.
| Print stage | Date | Size | ⠃ |
|---|---|---|---|
| Introduced in House | 2019-04-29 | 20.3K | ⠃⠗⠋ |
| Reported in House | 2020-12-24 | 20.9K | ⠃⠗⠋ |